Research-Only Notice & Compliance Boundary

This document is compiled strictly for educational and analytical reference purposes within laboratory, academic, and clinical research settings. The compounds discussed herein are supplied strictly as Research Use Only (RUO) chemicals and are not intended for human or veterinary consumption, diagnostic use, or therapeutic administration. Core Research does not provide dosing, reconstitution, or clinical administration guidelines.

L-Carnitine is a conditionally essential, endogenously synthesised quaternary ammonium compound that occupies a foundational role in mitochondrial fatty acid oxidation research, making it one of the most extensively characterised small-molecule metabolic cofactors in contemporary biochemistry. For researchers working at the intersection of cellular bioenergetics, metabolic disease modelling, and mitochondrial dysfunction, few compounds offer the mechanistic breadth and experimental tractability that L-Carnitine provides within a single, well-defined molecular entity.

The compound’s research significance is not merely historical — it is actively expanding. Over the past decade, the scientific literature has witnessed a marked acceleration in L-Carnitine-related publications, driven by renewed interest in its roles beyond classical fatty acid transport. Investigators have begun interrogating its influence on acylcarnitine flux, mitochondrial membrane dynamics, oxidative stress modulation, and even epigenetic regulatory pathways. This broadening of scope has repositioned L-Carnitine from a narrowly defined metabolic shuttle to a pleiotropic research tool capable of illuminating diverse aspects of cellular physiology and pathophysiology.

From a laboratory perspective, L-Carnitine’s appeal lies in its chemical stability under controlled conditions, its well-characterised interaction with carnitine palmitoyltransferase I and II (CPT-I and CPT-II), and its amenability to quantification via established analytical platforms including liquid chromatography–tandem mass spectrometry (LC-MS/MS) and nuclear magnetic resonance (NMR) spectroscopy. These properties make it an ideal reference compound for metabolic flux studies, isotopic tracer experiments, and in-vitro mitochondrial respiration assays.

Within the research compound catalogue at Core Research, L-Carnitine is classified under the metabolism research category and is supplied as a high-concentration aqueous solution at 600 mg/ml — a formulation decision grounded in both analytical practicality and long-term stability considerations. This overview is designed to serve as a comprehensive reference for investigators seeking to understand the compound’s identity, physicochemical properties, pre-clinical evidence base, and the specific formulation rationale that underpins our laboratory-grade preparation.

L-Carnitine — formally designated (3R)-3-hydroxy-4-(trimethylammonio)butanoate — is a zwitterionic, water-soluble small molecule belonging to the class of quaternary ammonium compounds. Its molecular formula is C₇H₁₅NO₃, yielding a molecular weight of 161.20 g/mol. The compound’s defining structural feature is its chiral centre at the C-3 position, which confers the biologically active (R)-configuration — the L-enantiomer — as distinct from the metabolically inert D-Carnitine. This stereochemical specificity is of paramount importance in research contexts: only the L-form participates in the carnitine acyltransferase reaction cycle, and investigators must therefore exercise rigorous quality control to confirm enantiomeric purity when sourcing material for mechanistic studies.

The molecular architecture comprises a four-carbon backbone bearing a hydroxyl group at the beta position, a carboxylate moiety at the terminal carbon, and a trimethylammonium group at the alpha-nitrogen. This arrangement produces a permanent positive charge at physiological pH, balanced by the carboxylate anion, rendering the molecule zwitterionic across a broad pH range. The consequence for laboratory handling is significant: L-Carnitine exhibits exceptional aqueous solubility — exceeding 600 mg/ml under standard conditions — and demonstrates negligible solubility in non-polar organic solvents such as diethyl ether or chloroform. This hydrophilicity profile directly informs formulation strategy, as aqueous vehicles are unambiguously the preferred matrix for high-concentration research preparations.

From a physicochemical standpoint, L-Carnitine presents as a white to off-white hygroscopic crystalline solid in its pure form, with a melting point in the range of 195–197 °C (with decomposition). Its pKa values — approximately 3.8 for the carboxylate and greater than 12 for the ammonium group — confirm its zwitterionic character across the physiologically and experimentally relevant pH window of 4–9. The compound’s optical rotation is [α]_D²⁰ = −29° to −32° (c = 5, H₂O), a parameter routinely employed in quality control assessments to verify stereochemical integrity.

Biosynthetically, L-Carnitine is produced endogenously in mammals via a multi-step pathway originating from the amino acids lysine and methionine, with the final hydroxylation step catalysed by γ-butyrobetaine dioxygenase — an iron- and ascorbate-dependent enzyme. This biosynthetic dependency on micronutrient cofactors has made L-Carnitine a valuable probe in studies examining the interplay between nutritional status and mitochondrial function. For research compound synthesis, however, chemical routes are preferred, typically involving the asymmetric synthesis of (R)-epichlorohydrin or the resolution of racemic carnitine via diastereomeric salt formation, followed by rigorous chiral HPLC verification to confirm enantiomeric excess (ee) values exceeding 99%.

Thermal stability profiling indicates that L-Carnitine in aqueous solution is susceptible to degradation under prolonged exposure to elevated temperatures (above 60 °C) and strongly acidic or alkaline conditions, with the primary degradation pathway involving dehydration to form crotonobetaine. Oxidative degradation, whilst less rapid than thermal pathways, is a meaningful concern at high concentrations in the presence of dissolved oxygen — a consideration that directly shaped the nitrogen-purging strategy employed in our laboratory preparation, as detailed in Section 4.

The pre-clinical research landscape surrounding L-Carnitine is extraordinarily rich, spanning decades of in-vitro mechanistic work, rodent model investigations, and more recently, sophisticated multi-omics analyses that have substantially refined our understanding of its biological roles. At its mechanistic core, L-Carnitine functions as an obligate carrier molecule for the translocation of long-chain fatty acyl groups across the inner mitochondrial membrane — a process that is rate-limiting for mitochondrial beta-oxidation and therefore central to cellular energy homeostasis. The carnitine shuttle system, comprising CPT-I on the outer mitochondrial membrane, carnitine-acylcarnitine translocase (CACT) within the inner membrane, and CPT-II on the matrix face, has been extensively modelled in isolated mitochondrial preparations and permeabilised cell systems, with L-Carnitine serving as both substrate and experimental probe.

When selecting L-Carnitine as a research compound, investigators must evaluate several critical technical parameters that directly influence experimental reproducibility, analytical accuracy, and long-term compound integrity. The following table summarises the key specifications relevant to laboratory-grade L-Carnitine at 600 mg/ml, contextualised against recognised research standards and their mechanistic implications for experimental design.

All specifications reflect Core Research’s internal quality control standards for Research Use Only (RUO) material. Batch-specific certificates of analysis (CoA) are available upon request and include full chromatographic trace data.

Regulatory Compliance

L-Carnitine supplied by Core Research is classified strictly as a Research Use Only (RUO) compound in accordance with applicable UK and EU in-vitro diagnostic and research reagent regulations. It does not hold Medicines and Healthcare products Regulatory Agency (MHRA) authorisation as a medicinal product, and its supply is governed by the Research Exemption provisions under UK law. Institutions procuring this material are responsible for ensuring that its use falls within the scope of their own institutional ethics approvals, Home Office project licences (where animal work is involved under the Animals (Scientific Procedures) Act 1986), and any applicable COSHH risk assessments under the Control of Substances Hazardous to Health Regulations 2002.

Professional Standards: GMC, HCPC & Institutional Oversight

Researchers who are registered healthcare professionals — including those regulated by the General Medical Council (GMC) or the Health and Care Professions Council (HCPC) — must ensure that their engagement with research compounds does not contravene their respective codes of professional conduct. In particular, the use of RUO compounds in any context that could be construed as clinical practice, off-label prescribing, or patient-directed intervention falls outside the scope of this supply arrangement and would constitute a serious professional boundary violation. Principal investigators bear institutional responsibility for ensuring that all team members, including postgraduate researchers and visiting scientists, are appropriately briefed on these boundaries prior to commencing experimental work.

Safeguarding: Adult & Child Populations

Research compounds must never be administered to, or made accessible to, vulnerable adults or children under any circumstances. Institutions must maintain secure compound storage with restricted access protocols, and any suspected misuse or diversion of research material must be reported immediately to the designated institutional safeguarding lead and, where appropriate, to the relevant statutory authority. Core Research reserves the right to suspend supply to any institution where safeguarding concerns are identified.

Data Protection & Secure Reporting

All research data generated using Core Research compounds must be handled in accordance with the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018. Where research involves human-derived biological samples, appropriate consent frameworks and data anonymisation protocols must be in place prior to experimental commencement. Adverse event reporting — including any unintended human or animal exposure to research compounds — should follow the institution’s standard operating procedures and, where required, be escalated to the relevant regulatory authority without delay.

Why is enantiomeric purity so critical when sourcing L-Carnitine for mechanistic research?

Only the (R)-enantiomer is recognised by CPT-I and CPT-II. D-Carnitine contamination introduces competitive inhibition artefacts that distort beta-oxidation flux measurements. Experienced investigators routinely request chiral HPLC traces alongside standard CoA documentation before commencing isotopic tracer experiments.

What is the rationale for the 600 mg/ml concentration in the Core Research formulation?

This concentration maximises volumetric efficiency for serial dilution protocols whilst remaining within L-Carnitine’s aqueous solubility ceiling. Researchers working with high-throughput mitochondrial respiration platforms find this concentration particularly practical for preparing working stocks without solvent-related confounders.

How should researchers handle repeated freeze-thaw cycles with the aqueous solution?

Repeated freeze-thaw cycles accelerate oxidative degradation and may alter osmolality. Best practice involves aliquoting into single-use volumes upon receipt. Laboratory teams conducting longitudinal studies consistently report improved analytical reproducibility when aliquot sizes are matched to individual experimental run requirements.

Can L-Carnitine be used as an internal standard in acylcarnitine profiling by LC-MS/MS?

Unlabelled L-Carnitine is not suitable as an internal standard due to endogenous matrix interference. Stable isotope-labelled variants (e.g., [²H₃]-L-Carnitine) are the validated choice. Investigators experienced in newborn screening metabolomics routinely use isotopically labelled analogues to correct for ion suppression effects.

What in-vitro cell models are most commonly employed in L-Carnitine research?

Primary hepatocytes, skeletal muscle myotubes (C2C12), and cardiomyocyte-derived cell lines are the most widely utilised models. Researchers investigating insulin resistance frequently employ 3T3-L1 adipocytes, noting that L-Carnitine supplementation in these models reliably modulates lipid accumulation phenotypes under high-fat conditions.

Is sterile filtration the appropriate sterilisation method for the aqueous solution?